History
2024: Partnership with Gedeon Richter
Gedeon Richter has become a strategic investor in Formycon. Gedeon Richter announced this on February 5, 2024.
As part of the successful cooperation in the field of contract development and production, the company invested funds in the amount of 9.08% of the share capital.
Gross revenue amounted to 82.84 million euros and is aimed at maintaining the high development rate of Formycon.
The transaction opens up the possibility of joint long-term strategic prospects in the field of development, production and commercial sale of drugs.
Both companies, whose experience and strategies have much in common, are convinced of the high potential of biosimilars. Combining the efforts of Formycon as an independent developer focusing on biosimilars and Gedeon Richter as a large international company with a large expertise in scientific development and manufacturing will provide patients with more opportunities, facilitating access to effective biological therapies.
Based on the decisions of Formycon's board and supervisory board, Gedeon Richter gave its consent for a 9.08% capital increase in a private offering. The registered share capital of the company will be increased by EUR 1,603,877,00 by partially using the share capital from the current EUR 16,053,025,00 to the total amount of EUR 17,656,902,00 by issuing 1,603,877 new bearer shares without the declared value, the nominal value of each of which will be EUR 1.00 of the share capital. The offering price of one new share is EUR 51.65 and represents the average value between the current closing price under the World Electronic Securities Trading System and the weighted average share price for the last thirty trading days. The rights of shareholders to acquire new shares were excluded in accordance with § 4 (3) of the Charter. Gedeon Richter will have a generally accepted 180-day ban on the sale of shares.
The total inflow of funds to Formycon is 82.84 million euros and will be used primarily for the further development of the company's existing line of biosimilars, in particular, FYB206, FYB208 and FYB209. In addition, the launch of FYB210, a new potential biosimilar, is scheduled for the second half of this year.
Шаблон:Quote 'author = said Gabor Orban, CEO of Gedeon Richter.
Шаблон:Quote 'author = noted Stefan Glombitza, CEO of Formycon AG.
Шаблон:Quote 'author = narrated by Enno Spilner, CFO of Formycon.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |